Cargando…

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials

Basal insulin peglispro (BIL) is a novel basal insulin with hepato‐preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, including three double‐blind trials. Prespecified pool...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Marre, Michel, Qu, Yongming, Zhang, Shuyu, Bastyr, Edward J., Prince, Melvin J., Chang, Annette M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096011/
https://www.ncbi.nlm.nih.gov/pubmed/27484021
http://dx.doi.org/10.1111/dom.12757
_version_ 1782465393799987200
author Rosenstock, Julio
Marre, Michel
Qu, Yongming
Zhang, Shuyu
Bastyr, Edward J.
Prince, Melvin J.
Chang, Annette M.
author_facet Rosenstock, Julio
Marre, Michel
Qu, Yongming
Zhang, Shuyu
Bastyr, Edward J.
Prince, Melvin J.
Chang, Annette M.
author_sort Rosenstock, Julio
collection PubMed
description Basal insulin peglispro (BIL) is a novel basal insulin with hepato‐preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, including three double‐blind trials. Prespecified pooled analyses (n = 4927) included: patients with type 2 diabetes (T2D) receiving basal insulin only, those with T2D on basal‐bolus therapy, and those with type 1 diabetes (T1D). BIL treatment resulted in a 36–45% lower nocturnal hypoglycaemia rate compared with glargine, despite greater reduction in glycated haemoglobin (HbA1c) and higher basal insulin dosing. The total hypoglycaemia rate was similar in patients with T2D on basal treatment only, trended towards being higher (10%) in patients with T2D on basal‐bolus treatment (p = .053), and was 15% higher (p < .001) with BIL versus glargine in patients with T1D, with more daytime hypoglycaemia in the T1D and T2D groups who were receiving basal‐bolus therapy. In T1D, during the maintenance treatment period (26‐52 weeks), the total hypoglycaemia rate was not significantly different. There were no differences in severe hypoglycaemia in the T1D or T2D pooled analyses. BIL versus glargine treatment resulted in greater HbA1c reduction with less nocturnal hypoglycaemia in all patient populations, higher daytime hypoglycaemia with basal‐bolus therapy in the T1D and T2D groups, and an associated increase in total hypoglycaemia in the patients with T1D.
format Online
Article
Text
id pubmed-5096011
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-50960112016-11-09 Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials Rosenstock, Julio Marre, Michel Qu, Yongming Zhang, Shuyu Bastyr, Edward J. Prince, Melvin J. Chang, Annette M. Diabetes Obes Metab Themed Section‐bil Basal insulin peglispro (BIL) is a novel basal insulin with hepato‐preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, including three double‐blind trials. Prespecified pooled analyses (n = 4927) included: patients with type 2 diabetes (T2D) receiving basal insulin only, those with T2D on basal‐bolus therapy, and those with type 1 diabetes (T1D). BIL treatment resulted in a 36–45% lower nocturnal hypoglycaemia rate compared with glargine, despite greater reduction in glycated haemoglobin (HbA1c) and higher basal insulin dosing. The total hypoglycaemia rate was similar in patients with T2D on basal treatment only, trended towards being higher (10%) in patients with T2D on basal‐bolus treatment (p = .053), and was 15% higher (p < .001) with BIL versus glargine in patients with T1D, with more daytime hypoglycaemia in the T1D and T2D groups who were receiving basal‐bolus therapy. In T1D, during the maintenance treatment period (26‐52 weeks), the total hypoglycaemia rate was not significantly different. There were no differences in severe hypoglycaemia in the T1D or T2D pooled analyses. BIL versus glargine treatment resulted in greater HbA1c reduction with less nocturnal hypoglycaemia in all patient populations, higher daytime hypoglycaemia with basal‐bolus therapy in the T1D and T2D groups, and an associated increase in total hypoglycaemia in the patients with T1D. Blackwell Publishing Ltd 2016-08-31 2016-11 /pmc/articles/PMC5096011/ /pubmed/27484021 http://dx.doi.org/10.1111/dom.12757 Text en © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Themed Section‐bil
Rosenstock, Julio
Marre, Michel
Qu, Yongming
Zhang, Shuyu
Bastyr, Edward J.
Prince, Melvin J.
Chang, Annette M.
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
title Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
title_full Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
title_fullStr Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
title_full_unstemmed Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
title_short Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
title_sort reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
topic Themed Section‐bil
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096011/
https://www.ncbi.nlm.nih.gov/pubmed/27484021
http://dx.doi.org/10.1111/dom.12757
work_keys_str_mv AT rosenstockjulio reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials
AT marremichel reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials
AT quyongming reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials
AT zhangshuyu reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials
AT bastyredwardj reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials
AT princemelvinj reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials
AT changannettem reducednocturnalhypoglycaemiawithbasalinsulinpeglisprocomparedwithinsulinglarginepooledanalysesoffiverandomizedcontrolledtrials